Zeta Research Srl © 2020. All rights reserved
P.IVA IT01028800322
PREFER
development of a bio-compatible product for the therapy of difficult wounds
Difficult wounds include all skin lesions, characterized by the absence or low speed of healing, resulting from chronic pathologies, infections, diabetes, immune diseases, trauma, amputations, post-operative complications, etc. These are serious diseases that can lead to amputation and which are widespread especially in the elderly population (prevalence 3% of the population over 65 years). Only in Italy it is estimated that there are 2 million individuals afflicted with these pathologies.
PREFER is a project which aims to create an Advanced Therapy Medicinal Product (ATMP) that is able to revascularize the tissues affected by such wounds, and by doing so, to heal them.
IN VITRO PRE-CLINICAL STUDY
IN VIVO PRE-CLINICAL STUDY
ATMP
Perform in-vivo efficacy tests to evaluate healing from a clinical, histological and functional point of view.
Commercialize the medicinal product to be developed thanks to its low cost production with automated bioreactors.
Identification, evaluation and use of extracellular matrices to support the growth of human endothelial cells.
30
€ 1.102,085
€ 718.486,92
MONTHS
TOTAL BUDGET
TOTAL CONTRIBUTION
This project is funded by:
Programma Operativo del Fondo europeo di sviluppo regionale 2014-2020 del Friuli Venezia Giulia.
Do you want to learn more or receive material about PREFER?
Fill out our online form to send an e-mail to our team.
Zeta Research Srl © 2020. All rights reserved
P.IVA IT01028800322